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Retrotransposons are mobile genetic elements that invade
eukaryotic genomes and then spread via a ‘‘copy-and-paste’’ mech-
anism [1,2]. Retrotransposition is a powerful mutagenic process
that can completely alter the complexity, size and structure of a
genome over a comparatively brief evolutionary timescale [3].
Specialised biological pathways have evolved to control the phe-
nomenon, particularly in plants and animals, where transposed
elements occupy a high percentage of genomic DNA [4–7]. Nearly
half of the human genome is derived from retrotransposons, trans-
posons and endogenous retroviruses, with the latter two classes
likely now including immobile elements only. Despite an overtly
parasitic pattern of replication, these sequences distinguish our
evolutionary history from that of other animals. For instance, inac-
tivation of CMP-N-acetylneuraminic acid hydroxylase by an Alu
retrotransposon subsequent to the Homo-Pan divergence is con-
sidered to have inﬂuenced human brain expansion [8]. Genome
structural variation generated by retrotransposons is also common
in humans and is linked to 75 diseases [9–13]. Thus, retrotrans-
position yields human-speciﬁc genetic diversity underlying pheno-
typic variation.
Three retrotransposon families are currently active in humans:
L1, Alu and SVA (Fig. 1). L1 is considered the master controller ofchemical Societies. Published by Eretrotransposition [14]; its two open reading frames encode pro-
teins [15–17] capable of mobilising L1 RNAs in cis as well as a host
of other RNAs in trans, including those produced by Alu, SVA and in
some cases protein-coding genes [18–21]. Ostensibly due to the
low processivity of the L1 reverse transcriptase, the vast majority
of retrotransposon-derived sequences in the genome have been
immobilised by truncations, as well as inversions [22] and other
mutations. As ﬁrst hypothesised by McClintock and later devel-
oped by Britten and Davidson [2,23], these transposed elements
provide raw material for gene regulation circuits. More recent
experiments suggest that transposed elements are widely tran-
scribed and only partially repressed by the same epigenetic marks
that control their transposition-competent relatives [24–26].
Post-translational modiﬁcation of histone tails (e.g., acetylation,
methylation) and DNA methylation are the primary mechanisms
that inhibit retrotransposon mobilisation. In human,MECP2 associ-
ates with its co-repressors HDAC1, HDAC2 and SOX2 to silence the
canonical L1 50 promoter [27–29]. Removal of this epigenetic
repression enables transcription factors, such as RUNX3 and YY1
[30,31], to bind to the L1 promoter and direct PolII to produce a
full-length L1 RNA. If this RNA can then avoid a second level of less
stringent genome surveillance based on the RNAi [32] and RNA
editing [33,34] pathways it can be translated to generate the L1
transposition machinery. Acting in cis, this complex produces
new L1 copies via target-primed reverse transcription (TPRT) [35].
The speciﬁc mechanism of retrotransposition varies across fam-
ilies. Alu for instance is transcribed from an internal PolIII promoterlsevier B.V. All rights reserved.
Fig. 1. Active human retrotransposon consensus sequences. L1 is comprised of two open reading frames (ORFs) ﬂanked by 50 and 30 untranslated regions (UTRs). ORF1
contains coiled-coil (CC), RNA recognition motif (RRM) and carboxyl-terminal (CT) domains [15]. ORF2 encodes endonuclease (EN), reverse transcriptase (RT) and cysteine-
rich (C) domains [16,17]. Alu comprises two monomeric regions separated by a short, A-rich A5TACA6 consensus sequence. SVA is a composite element combining a hexamer
repeat (CCCTCTn) with two SINEs separated by a variable-number-of-tandem repeats (VNTR) region. The 50 SINE resembles an Alu whereas the 30 SINE is derived from a long
terminal repeat (LTR) associated with a human endogenous retrovirus (HERV-K10) [20]. Each element typically generates a target site duplication (red arrows) upon
integration and incorporates a poly(A) tail. The 30 termini of L1 and SVA are marked by a polyadenylation signal (pA). L1 and Alu are transcribed from internal PolII and PolIII
promoters, respectively (blue boxes). Figure adapted from [1,9].
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transcription by PolII [37]. In some cases multiple ‘‘hot’’ retrotrans-
posons can mobilise from the same family [38] or, as in the case of
the rodent BC1 family, only the RNA of a single master gene can ini-
tiate retrotransposition [39]. Despite these variations, virtually all
retrotransposition follows the general pattern of (a) escape from
epigenetic and post-transcriptional repression, (b) transcription
of an RNA intermediate, (c) reverse transcription and (d) integra-
tion in a new locus. This review will explore genome-wide evi-
dence for germ line and somatic cell retrotransposition events in
the human population.
2. Retrotransposons, genome evolution and disease
Retrotransposition has mainly been observed in germ cells, dur-
ing very early embryonic development and in cultured carcinoma
cells [40–45]. Through studying these systems in depth, we now
have a reasonable understanding of the cellular and molecular
environments that allow an individual element to mobilise in the
human germ line. Earlier experiments also revealed which L1, Alu
and SVA subfamilies were active in humans compared to other pri-
mates [46,47]. Thus, we possess an almost certainly complete cat-
alogue of active human retrotransposon families and a reasonably
accurate model of when and how these elements mobilise during
development. A major objective is now to map and functionally
annotate as many novel integration sites as possible and calculate
the frequency of each in the global population.
2.1. High-throughput approaches to map retrotransposon insertions
The full-length nucleotide sequences of L1, Alu and SVA were
ﬁrst produced by cloning and sequencing repetitive DNA resistant
to endonuclease treatment (Alu) [48], through cDNA sequencing
(L1) [49] and through sequencing elements found in cloned pro-
tein-coding genes (SVA) [20]. The landmark discovery that retro-
transposition was still occurring in humans, and indeed could
cause disease [50], greatly increased efforts to ﬁnd recent inser-
tions and characterise retrotransposon subfamilies. However, the
catalogue of loci containing active retrotransposons grew slowly
until higher-throughput approaches were developed to map retro-
transposon integration sites a priori. An important precursor to
these approaches, dubbed L1 display, was developed to screen
large human cohorts for dimorphic elements [51,52]. As broadly
summarised in Fig. 2A, L1 display exploited an ACA trinucleotide
diagnostic for the L1-Ta subfamily [38] to detect the 30 terminusand ﬂanking region of recent L1 insertions. A primer incorporating
this ACA was paired with an arbitrary 10mer to generate a PCR
amplicon that could be visualised by Southern blot [52]. Dimor-
phism was conﬁrmed by the absence or presence of a band in a gi-
ven human population.
L1 display was subsequently modiﬁed to incorporate suppres-
sion PCR and capillary sequencing in an approached called ATLAS
[53]. Loci containing dimorphic L1s could be identiﬁed by ATLAS
after clones were aligned to an early draft of the human genome
sequence produced by whole genome shotgun sequencing (WGSS).
In addition to a complete reference genome, which improved the
resolution of ATLAS, WGSS also identiﬁed numerous retrotranspo-
son insertions of low allelic frequency [4,7,54–57], suggesting that
high-throughput methods would be necessary to map rare
insertions.
Several groups have recently presented techniques to screen
hundreds of individuals for germ line retrotransposition events.
Each employed innovative variations to improve the throughput
and enrichment for target sequences achieved by ATLAS. Ewing
and Kazazian [58] used hemi-speciﬁc PCR to amplify the 30 ﬂanking
region of recent L1 insertions, followed by Illumina deep sequenc-
ing (Fig. 2B). Beck et al. [59] subjected fosmid libraries to a series of
screens, including ATLAS, to isolate the ﬂanking regions of full-
length and near full-length L1 sequences (Fig. 2C). Huang et al.
[60] applied transposon insertion proﬁling by microarray (TIP-
chip) technology developed in yeast [61] to Alu and L1. Focusing
on L1, they made substantial modiﬁcations to ATLAS by digesting
DNA 1-5kb from the L1 30 terminus (Fig. 2A), followed by liga-
tion-mediated PCR (LM-PCR) and hybridisation to genome-wide
tiling arrays (Fig. 2D). Iskow et al. [62] also used restriction endo-
nucleases and LM-PCR to amplify L1 and Alu (L1-seq and Alu-seq,
respectively) but performed capillary and 454 sequencing to locate
novel insertions with respect to the reference genome (Fig. 2E).
These technologies massively expanded the available catalogue
of L1 and Alu polymorphic insertion sites [56]. However, each ap-
proach varied considerably in terms of sensitivity, a major consid-
eration if the primary goal was to generate a complete list of
retrotransposon integration sites in an individual genome without
resorting to WGSS. The method of Beck et al. [59] presented a low
false-positive rate and, through screening fosmids for the L1 50UTR
before sequencing, was by design an excellent way to detect hot
L1s. A consequential bias towards longer insertions, which are far
less common than the short 30 fragments produced by L1 retro-
transposition, and a reliance on capillary sequencing, meant that
the approach intentionally detected a minority of L1 insertions.
Fig. 2. High-throughput strategies to identify recent L1 insertions. (A) Enrichment for L1 30 junction sequences [52,53]. An L1 primer incorporating the ACA trinucleotide
diagnostic for hot L1s is coupled with a random primer, followed by PCR. Alternatively, ampliﬁcation is achieved through digesting DNA with one or several restriction
enzymes (purple circle) followed by ligation-mediated PCR (LM-PCR). (B) To enable deep sequencing, ﬁrst round PCR products are further ampliﬁed by hemi-speciﬁc nested
PCR before single-end sequencing with the Illumina platform [58]. (C) Alternatively, ﬁrst round PCR products are cloned and sequenced by capillary sequencing [59]. (D)
Without further ampliﬁcation, LM-PCR products are hybridised to whole-genome tiling arrays [60]. (E) First round LM-PCR products are cloned and sequenced by capillary or
454 sequencing [62]. Note that the schematic is only representative of each technique. For instance, the method of Beck et al. (C) screens fosmid libraries before enrichment is
achieved in (A) [59].
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outlier in its use of tiling arrays to resolve insertion loci [60]. This
simpliﬁed sample preparation and data interpretation greatly,
meaning that the approach has substantial promise for genotyping.
As Huang et al. acknowledge, however, tiling array probes are by
necessity designed away from repetitive elements to avoid cross-
hybridisation. Given that half of the human genome is comprised
of transposed elements, TIP-chip may have failed to detect an
equivalent proportion of insertion sites.
Iskow et al. exploited high-throughput sequencing to assay nor-
mal and cancer samples for germ line insertions and also made the
pivotal observation that somatic L1 retrotransposition occurred in
lung tumours [62]. One of the more noticeable and unexplained
statistics arising from this data was that, of several hundred thou-
sand 454 reads produced by L1-seq and Alu-seq, fewer than 25%
could be aligned to the reference genome, despite sequencing from
the 30 end to avoid L1 and Alu poly(A) tails. Other than the most
obvious explanation of low sequencing quality, this could also be
due to the fact that many of the samples used were tumours,
where indels and other structural variants could obstruct longer
alignments to the reference genome.
Ewing and Kazazian detected a similarly large number of inser-
tions, using fewer samples, through short read (76mer) single-end
sequencing [58]. This approach therefore achieved the highest cov-
erage of polymorphic L1 retrotransposition events per individual.
Previous results and calculations for short read data [25,63,64]
suggest that a 76mer has sufﬁcient speciﬁcity to uniquely map to
the majority of transposed elements, excluding a small minority
of very recent insertions. Paired-end reads could have been used
to trace a subset of new insertions back to hot L1s on the genome,
but would also have nearly doubled the cost of sequencing. Overall,
though it should be emphasised that each of the four methods was
designed with substantially different applications in mind, the
depth achieved by the Ewing and Kazazian method probablyprovided the most comprehensive detection of recent L1 insertions
in a given sample.
2.2. Retrotransposon insertion polymorphisms in human populations
When combined with large-scale WGSS projects [65], high-
throughput screening of retrotransposon insertion sites has pro-
vided accurate estimates of L1 and Alu activity in the global human
population, in addition to preliminary calculations based on a
smaller pool of SVA polymorphisms [57]. It is clear that structural
and genetic variation caused by retrotransposition is widespread.
For Alu, comparisons between human individuals and other prima-
tes, as well as calculations based on the frequency of disease caus-
ing insertions, have produced a consensus of 1 de novo insertion
for every 20 live births [55,57,66], a 10-fold increase over estimates
from the pre-genome era [10].
By contrast, estimates of L1 retrotransposition rate were revised
substantially downward in the past decade. Early calculations
based on the frequency of disease causing L1 mutations suggested
a rate of 1 insertion per 20 live births [67]. More recently, compar-
isons between individual genome sequences placed the retrotrans-
position rate at 1/200 births [57] and the high-throughput
screening methods highlighted above again revised this to
1/100–1/150 births [58,60]. As others have suggested, the substan-
tial differences between disease-based and sequencing-based
calculations may be due to strong selection against new L1 inser-
tions [9,58].
In terms of transposition competent elements, the human
genome on average contains 80–100 L1s, 2000–3000 Alus and
probably fewer than 100 SVAs, with each presenting a sub pool
of hot elements [36,38,68,69]. If these contribute 1 new insertion
per 150, 20 and 1000 live births for L1, Alu and SVA [57], respec-
tively, the global human population of 6.8 billion individuals
would be expected to contain in the order of 392 million private
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SVA). Prior estimates based on WGSS suggested that any two indi-
viduals would likely differ by approximately 180 L1, 1283 Alu and
56 SVA polymorphisms [68] and, as most of these occur in more
than 1% of the population, deeper screening has not substantially
altered these ﬁgures [58,60]. Given such vast diversity it is easy
to appreciate why high-throughput strategies designed to detect
retrotransposon insertions are necessary.
In the future these approaches could be applied to discover the
genetic aetiology of diseases in the same manner as a genome-
wide association study (GWAS). In a pilot experiment, TIP-chip
found intronic L1 insertions in two protein-coding genes of possi-
ble functional signiﬁcance for patients afﬂicted by one of several X-
linked disorders [60]. Though these data were inconclusive,
numerous diseases have previously been associated with heritable
and de novo retrotransposition events [9,50] and it is likely that
high-throughput screening applied to larger patient cohorts would
reveal pathogenic polymorphisms. This could be achieved through
modiﬁed or hybrid versions of each technique discussed above
(e.g., L1-seq combined with Illumina sequencing or TIP-chip probes
attaining lower cross-hybridisation rates) and will be assisted by
ongoing reductions in sequencing and microarray costs.
3. Somatic retrotransposition during neurogenesis
Germ line retrotransposition events are, as noted above, an
important source of heritable genetic variation [70]. However, re-
cent assays have suggested that most de novo insertions occur dur-
ing embryogenesis and, perhaps to a lesser extent, in later
development [43,71]. These mutations generate intra-individual
variation where genetically distinct somatic cells form a genome
mosaic in a particular organ or system [27,72]. Somatic genome
mosaicism violates a central tenet of biology: apart from very lim-
ited exceptions, such as V(D)J recombination in immunoglobulin
genes [73], the normal somatic cells of the human body are consid-
ered genetically identical. Widespread genome structural variation
caused by retrotransposition during ontogenesis could fundamen-
tally alter the genotype-phenotype paradigm, in a similar fashion
to Waddington’s epigenetic landscape of the 1950s [74].
Perhaps the best evidence for somatic genome mosaicism arises
from L1 retrotransposition during neurogenesis [27,28,75,76]. In
this system, epigenetic repression of the L1 promoter is not ubiq-
uitous in neural precursors and committed neural cell lineages
[27,28]. Thus, hot L1s can initiate transcription of full-length RNAs
[25,77,78] and mobilise to new genomic loci, without the need for
cell division [79]. Transposition has been observed directly in cul-
tured neural cells using transgenic L1s tagged with an EGFP repor-
ter cassette that ﬂuoresces upon integration [27,75] and indirectly
in vivo by detection of L1 copy number variation (CNV) across
adult human brain tissues [28,75].Fig. 3. Schematic representation of germ line and somatic retrotransposition events du
hexagon), embryonic (purple triangle), fetal (black squares) and post-natal (green circles
represent different mutations. Developmental progression is correlated with an increaseDespite these compelling experiments, further evidence is re-
quired in support of the somatic mosaicism model. Firstly, trans-
genic L1 retrotransposition rates probably do not perfectly
recapitulate levels in vivo. Secondly, the relative level of L1 mobi-
lisation during embryogenesis versus later development – a major
factor in producing genetic heterogeneity in adult cells – is not well
established. Thirdly, and most importantly, it is unknown which
genomic loci harbour somatic L1 insertions in the brain or else-
where. These data alone could conﬁrm the occurrence of somatic
mosaicism and, critically, could be used to link genetic changes,
including those in protein-coding regions, with phenotypic effects.
In an attempt to locate somatic L1 retrotransposon events in
early embryonic stages, Huang et al. applied TIP-chip to peripheral
blood leukocytes from phenotypically discordant monozygotic
twins [60]. No somatic events were detected. One explanation for
this is that waves of somatic retrotransposition throughout organ-
ogenesis could produce vastly different frequencies for each inser-
tion (Fig. 3). Therefore, the majority of retrotransposition events
could occur below the detection thresholds of TIP-chip, particularly
if further somatic activity in peripheral blood is less common than
in the brain. Though Iskow et al. detected somatic L1 retrotranspo-
sition in tumours with L1-seq, these mutations could be very com-
mon after clonal replication of cancer cells [62]. Mapping the
individual retrotransposition events that collectively form a so-
matic mosaic in a healthy tissue may pose an even more signiﬁcant
challenge to the ﬁeld.
It is intriguing that retrotransposition could create genetically
distinct cell subpopulations in the mammalian brain. The brain is
an incredibly complex organ, structurally and functionally, and
has well known regenerative and adaptive characteristics related
to plasticity and learning [80]. The genetic basis for most neurolog-
ical disorders is also poorly established [81]. Somatic mosaicism
could therefore be of major biological signiﬁcance [72]. Though
this viewpoint is highly speculative, it is plausible that neurode-
generative conditions such as Alzheimer’s disease and Parkinson’s
disease could involve somatic retrotransposition events that dysre-
gulate gene pathways underlying childhood and adult neurogene-
sis [80]. For instance, recent experiments indicated elevated L1
retrotransposition rates in the brains of Rett syndrome patients
[28]. From yet another perspective, a mutagenic system where
individual neurons are randomly afﬂicted by somatic retrotranspo-
son insertions could inactivate tumour suppressor genes as a pre-
lude to tumorigenesis. The relationship between somatic
retrotransposition and pathogenesis is currently almost entirely
unexplored; it equally possible that somatic retrotransposition is
necessary for normal biological processes or indeed has negligible
phenotypic effects.
Another open question is whether somatic L1 retrotransposition
would follow the same pattern as seen in the germ line, where
mutations in exons and introns are negatively selected [4]. DNAring the development of two neurons from different brain regions. Germ cell (red
) mutations are present in a somatic genome mosaic. Symbols in different locations
d probability of a retrotransposon insertion being dimorphic.
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the L1 endonuclease during TPRT [82]. If, for instance, a gene is
highly transcribed in neurons, implying an open chromatin state,
it would probably also be predisposed to retrotransposon inser-
tions that are not individually selected against during evolution.
Also, as others have shown, retrotransposons do not have to insert
in exons to have major functional consequences. Mutations in in-
trons, promoters, distal enhancers and other non-coding regions
can have pronounced effects [25,83–85]. In this way, somatic ret-
rotransposition could subtly alter the genetic and transcriptional
landscape of a cell to better suit a particular environmental niche
and, though these mutations would not be inherited per se, the
mosaic execution programme could be transmitted through the
germ line.
4. Conclusion
Genome-wide technologies have been developed to assess ret-
rotransposition events in germ and somatic cells, indicating major
inter- and intra-individual genetic diversity in humans. It is likely
that the same evolutionary arms race between retrotransposons
and their host genomes that has occurred over hundreds of mil-
lions of years will continue to produce structural variation in the
human genome. However, a divide remains between the detection
of retrotransposon insertions and linking these with phenotypic
consequences, particularly for somatic mobilisations. The chal-
lenge in this era of personalised genomics [65] will be to place ret-
rotransposon-derived variability in a functional context that
informs our basic understanding of healthy development and
pathogenesis.
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